Hold
Average UserHold
Average AnalystSlightly Bullish
Stock Target AdvisorUSD 174.30
-1.76 (-1.00)%
USD 67.64B
5.60M
USD 164.96(-5.36%)
Hold
Average UserHold
Average AnalystSlightly Bullish
Stock Target AdvisorUSD 67.64B
USD 174.30
Based on the Moderna Inc stock forecasts from 12 analysts, the average analyst target price for Moderna Inc is USD 164.96 over the next 12 months. Moderna Inc’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Moderna Inc is Slightly Bullish , which is based on 10 positive signals and 5 negative signals. At the last closing, Moderna Inc’s stock price was USD 174.30. Moderna Inc’s stock price has changed by -9.72% over the past week, -2.96% over the past month and +0.90% over the last year.
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and in...Read More
200 Technology Square, Cambridge, MA, United States, 02139
3,700
December
USD
USA
1.71
USD 217.25
2.00
USD 115.03
14,042,188
USD 155.71
14,041,300
USD 186.15
9.68%
4.96%
67.89%
N/A
Security | Capital Gain | Dividend Return | Total Return |
---|
Symbol | Name | Price(Change) | Market Cap | Price / Earning Ratio | EV/EBITDA |
---|---|---|---|---|---|
|
Vertex Pharmaceuticals Inc | -5.83 (-1.80%) | USD82.14B | 25.24 | 16.84 |
|
Regeneron Pharmaceuticals Inc | -0.47 (-0.06%) | USD80.20B | 15.52 | 12.07 |
|
Alexion Pharmaceuticals Inc | 0.00 (0.00%) | USD40.34B | 59.23 | 42.56 |
|
BioNTech SE | -0.36 (-0.25%) | USD34.86B | 3.27 | 2.14 |
|
Alnylam Pharmaceuticals Inc | -1.49 (-0.66%) | USD27.73B | N/A | -29.42 |
|
BeiGene Ltd | -1.72 (-0.67%) | USD26.95B | N/A | -9.58 |
|
Seagen Inc | -0.45 (-0.32%) | USD25.90B | 55.02 | -38.86 |
|
Genmab AS | -0.03 (-0.08%) | USD25.68B | 30.85 | 3.59 |
|
Biomarin Pharmaceutical Inc | +1.36 (+1.18%) | USD21.32B | 266.74 | 90.91 |
|
argenx NV ADR | -2.52 (-0.66%) | USD21.13B | N/A | -21.25 |
Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
---|---|---|---|---|---|
|
iShares Nasdaq US Biotech.. | 7.43 % | 0.00 % | -0.01 (-0.11%) | USD0.47B |
|
iShares Nasdaq US Biotech.. | 7.43 % | 0.35 % | -0.10 (-1.69%) | USD0.46B |
|
iShares IV Public Limited.. | 7.43 % | 0.35 % | +0.04 (+0.63%) | USD0.46B |
|
Direxion mRNA ETF | 7.08 % | 0.65 % | +0.18 (+1.16%) | USD4.43M |
|
Invesco Nasdaq Biotechnol.. | 6.74 % | 0.19 % | -0.01 (-0.05%) | USD0.02B |
|
BMO MSCI Genomic Innovati.. | 6.72 % | 0.40 % | +0.01 (+0.05%) | USD4.47M |
|
iShares Nasdaq US Biotech.. | 6.40 % | 0.35 % | -0.07 (-1.14%) | USD0.47B |
|
iShares Nasdaq US Biotech.. | 6.40 % | 0.35 % | -0.07 (-1.10%) | USD0.04B |
|
iShares Nasdaq US Biotech.. | 6.40 % | 0.35 % | -0.05 (-1.03%) | USD0.47B |
|
VanEck Biotech ETF | 5.82 % | 0.35 % | +0.10 (+0.06%) | USD0.54B |
|
iShares Biotechnology ETF | 5.73 % | 0.44 % | +0.16 (+0.12%) | USD8.94B |
|
ProShares Ultra Nasdaq Bi.. | 5.25 % | 0.95 % | -0.29 (-0.47%) | USD0.11B |
|
Pacer US Cash Cows Growth.. | 4.82 % | 0.60 % | -0.37 (-1.00%) | USD0.04B |
|
BMO MSCI Innovation Index.. | 4.43 % | 0.40 % | +0.72 (+3.17%) | USD0.02B |
|
ETFMG Treatments Testing .. | 4.13 % | 0.68 % | -0.10 (-0.40%) | USD0.02B |
|
iShares Genomics Immunolo.. | 4.08 % | 0.47 % | +0.27 (+1.00%) | USD0.17B |
|
iShares U.S. Tech Breakth.. | 3.85 % | 0.40 % | +0.79 (+2.58%) | USD0.34B |
|
Middlefield Healthcare & .. | 3.47 % | 0.85 % | 0.00 (0.00%) | USD0.09B |
|
Middlefield Healthcare Di.. | 3.47 % | 0.00 % | +0.10 (+0.91%) | N/A |
|
6 Meridian Quality Growth.. | 3.20 % | 1.00 % | +0.36 (+1.67%) | USD0.03B |
|
Horizons Global BBIG Tech.. | 3.14 % | 0.45 % | 0.00 (0.00%) | USD3.31M |
|
First Trust AlphaDEX U.S... | 3.09 % | 0.79 % | 0.00 (0.00%) | USD0.02B |
|
Strategy Shares Halt Clim.. | 2.20 % | 0.95 % | +0.18 (+0.82%) | USD1.09M |
|
First Trust Health Care A.. | 2.18 % | 0.61 % | +1.28 (+1.14%) | USD1.66B |
|
BMO Equal Weight US Healt.. | 2.07 % | 0.39 % | +1.19 (+1.66%) | USD0.43B |
|
Invesco S&P 500 GARP ETF | 2.04 % | 0.33 % | +1.48 (+1.65%) | USD2.34B |
|
iShares Healthcare Innova.. | 1.70 % | 0.40 % | +0.02 (+0.28%) | USD1.41B |
|
iShares Healthcare Innova.. | 1.70 % | 0.40 % | +2.25 (+0.36%) | USD1.42B |
|
Mackenzie Maximum Diversi.. | 1.68 % | 0.55 % | +0.05 (+0.19%) | USD0.38B |
|
Mackenzie Maximum Diversi.. | 1.65 % | 0.50 % | +0.14 (+0.43%) | USD0.15B |
|
Invesco NASDAQ 100 Equal .. | 1.15 % | 0.25 % | 0.00 (0.00%) | USD5.60M |
|
First Trust US Large Cap .. | 0.75 % | 0.75 % | -0.02 (-0.03%) | USD0.10B |
|
First Trust Global Funds .. | 0.75 % | 0.75 % | +0.26 (+0.42%) | USD0.10B |
|
First Trust Multi Cap Gro.. | 0.73 % | 0.65 % | +1.30 (+1.29%) | USD0.17B |
|
Invesco RAFI Strategic US.. | 0.31 % | 0.23 % | +0.65 (+1.77%) | USD0.10B |
|
AGFiQ US Market Neutral A.. | 0.21 % | 0.55 % | -0.43 (-2.26%) | USD0.37B |
|
First Light Acquisition G.. | 0.00 % | 1.44 % | +0.01 (+0.10%) | USD0.10B |
|
BMO Equal Weight US Healt.. | 0.00 % | 0.39 % | 0.00 (0.00%) | USD0.05B |
|
First Trust AlphaDEX US H.. | 0.00 % | 0.77 % | 0.00 (0.00%) | USD0.02B |
|
Middlefield Healthcare & .. | 0.00 % | 0.85 % | -0.03 (-0.24%) | USD0.05B |
Heading 1 | Heading 2 | Heading 3 | Heading 4 | Heading 5 |
---|---|---|---|---|
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
The company had positive total cash flow in the most recent four quarters.
The company had positive total free cash flow in the most recent four quarters.
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
The stock is trading high compared to its peers median on a price to book value basis.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.